Cannabix Technologies Makes Advances with Marijuana Breathalyzer Development and THC Breath Capture
July 15, 2019
Vancouver, British Columbia, July 15, 2019 -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”) developer of the Cannabix Marijuana Breathalyzer for law enforcement and the workplace, is pleased to report that Company scientists have made significant advancements with analyte in breath capture and FAIMS cell development. Cannabix scientist having been optimizing the breath / sample capture procedures and technology to maximize ∆9-tetrahydrocannabinol (“THC”) analyte capture from human breath. THC is found in breath in generally low quantities. The Company has significantly improved sample collection methods using the breath collection unit (“BCU”) and other newly developed techniques. In addition, engineers have developed a proprietary next generation FAIMS cell that is currently being tested. The Company has been steadily progressing with human breath testing at its Vancouver, BC, based lab with its FAIMS (field asymmetric waveform ion mobility spectrometry) THC detection device and BCU.
Comment on Saliva Testing
“We would like to make it clear that roadside saliva tests are not “breathalyzers” and do not represent the promise of breath testing for roadside marijuana impairment. It is apparent that existing saliva-testing devices are being used in some jurisdictions because no regulatory evidential breath testing devices currently exist on the market. Cannabix and our product development work is dedicated to the development of marijuana breathalyzer technologies. Saliva testing, also known as “oral swab testing” is not new technology and has been available for many years. There are well documented issues with saliva testing including its ability to effectively identify impaired individuals and operate in cold weather conditions, to name a few. There are a growing number of examples of the lack of confidence in saliva testing devices. In 2018, Vermont Senate Judiciary Committee rejected a bill authorizing the use of saliva testing in traffic enforcement, amid concerns of scientific validity, accuracy, and infringement on civil liberties. In 2019, a Nova Scotia woman initiated the first court challenge in Canada related to saliva testing, where she claims she tested positive for THC, several hours after she used medical marijuana. Most police detachments have not adopted saliva testing to date, opting for better technology options that are being developed.
Cannabix believes that an accurate evidential breath testing device for THC is the future for law enforcement and workplace testing, as it is less invasive and will look to provide superior method to better determine impairment. It is well documented that breath is a better indicator of impairment than saliva, blood, or urine because THC only remains in breath for short period of time (2-3 hours) before becoming virtually undetectable, whereas it can remain in other body fluids for many hours, days, or even weeks after smoking. This short time period of detection in breath aligns with the peak impairment window.
The Company has received significant interest for its technology from police and companies in the U.S., Canada and elsewhere. As the issue of drugged driving becomes increasingly acute, Cannabix is committed to using its technology, R&D and scientific experience to provide effective tools to aid law enforcement and help governments and the public transition to marijuana legalization in various jurisdictions. Cannabix is a well funded Canadian company that is rapidly developing its marijuana breathalyzer technology.”
The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, Cannabix Technologies Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.